CR CRDF Cardiff Oncology, Inc. Loading... : Bullish and Bearish Analyst Opinions

The author is bullish on Cardiff Oncology (CRDF) because onvansertib targets first-line RAS-mutated metastatic colorectal cancer, a large underserved market, with recent readouts suggesting it beats standard-of-care and a Phase 3 targeted for Q1 2027 after a successful End of Phase 2 FDA meeting. The author was drawn in by Gary Pace's roughly $1M insider purchase at a cost average near $1.50, above the current price, and expects progress in Cardiff's California lawsuit against NMS over patent inventorship to lift shares. The author believes NMS is using the joint inventorship claim as a negotiation tactic to reprice the 2017 license, and views court progress as a near-term catalyst. The main risk is the legal dispute itself, including NMS's attempt to terminate the agreement and the possibility of an unfavorable ruling.

The author bought Cardiff Oncology (CRDF) after Gary Pace's insider purchase of over $1M, viewing the insider's cost basis as an anchor since the stock has not yet reached it. The stated catalyst is positive news from the court case with NMS; the author argues even a preliminary injunction, not just a full settlement, would send shares higher. The main risk implied is that the court case outcome is uncertain and the thesis depends on a favorable legal development.

JPMorgan, Deutsche Bank, Mizuho, Oppenheimer, Daiwa, Citizens, BTIG, William Blair, Jefferies, Berenberg, Raymond James, and China Renaissance issue multiple upgrades and downgrades with price target changes across a broad set of stocks.